Kalaris Therapeutics, Inc. lost $2.85 per diluted share in fiscal year 2025. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $2.02 per diluted share. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Kalaris Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$2.85
Ticker history: ALVR became
KLRS
(Kalaris Therapeutics, Inc.) on .
Earlier news and filings retain their original names and dates.
View ALVR history.
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
KLRS EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Kalaris Therapeutics, Inc. lost $2.85 per diluted share in fiscal year 2025.
Kalaris Therapeutics, Inc. (KLRS) reported a loss of $2.02 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
Across the 7 fiscal years this page covers, Kalaris Therapeutics, Inc. (KLRS) diluted earnings per share went from -$18.54 in fiscal year 2019 to -$2.85 in fiscal year 2025.
Kalaris Therapeutics, Inc. (KLRS) reported -$0.48 in diluted earnings per share in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Kalaris Therapeutics, Inc. (KLRS) reported on that line in every period on record.
